Global surveillance through PROTEKT: The first year

Journal of Chemotherapy

Volumn 14, Issue SUPPL. 3, 2002, Pages 9-16

  Gruneberg R N ^a  

^a GR Micro   (United Kingdom)

Author keywords

Genotype; Haemophilus influenzae; Moraxella catarrhalis; PROTEKT; Streptococcus pneumoniae; Surveillance; Telithromycin

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAMASE; CEFACLOR; CEFDINIR; CEFDITOREN; CEFPROZIL; CEFUROXIME; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; LEVOFLOXACIN; LINEZOLID; MACROLIDE; MOXIFLOXACIN; PENICILLIN G; TEICOPLANIN; TELITHROMYCIN; TETRACYCLINE; VANCOMYCIN;

ACCURACY; ANTIBIOTIC RESISTANCE; ARTICLE; DRUG SURVEILLANCE PROGRAM; EMPIRICISM; GEOGRAPHIC DISTRIBUTION; HAEMOPHILUS INFLUENZAE; HEALTH CARE POLICY; INFORMATION PROCESSING; MORAXELLA CATARRHALIS; MULTIDRUG RESISTANCE; NONHUMAN; PREVALENCE; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

EID: 0036661169     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1080/1120009x.2002.11782347     Document Type: Article

References (20)

1. The World Health Report. Conquering suffering, enriching humanity. Geneva: World Health Organization, 1997.
2. Felmingham D, Washington J, & The Alexander Project Group. Trends in antimicrobial susceptibility of bacterial respiratory tract pathogens - findings of the Alexander Project 1992-1996. J Chemother 1999; 11: 5-21.
3. Sahm DF, Jones ME, Hickey, ML, Diakun DR, Mani SV, Thornsberry C. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in Asia and Europe, 1997-1998. J Antimicrob Chemother 2000; 45: 457-66.
4. Hoban DJ, Doern GV, Fluit AC, Roussel-Delvallez M, Jones RN. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the SENTRY antimicrobial surveillance program, 1997-1999. Clin Infect Dis 2001; 32 (suppl 2): S81-93.
5. Sethi S. Infectious exacerbations of chronic bronchitis: diagnosis and management. J Antimicrob Chemother 1999; 43 (Suppl A): 97-105.
6. Honeybourne D. Community-acquired pneumonia in ambulatory patients: relative importance of atypical pathogens. Int J Antimicrob Agents 2001; 18 (suppl 1): S57-61.
7. Klugman KP. Pneumococcal resistance to antibiotics. Clin Microbiol Rev 1990; 3: 171-96.
8. Blondeau JM, Tillotson GS. Antimicrobial susceptibility patterns of respiratory pathogens-a global perspective. Semin Respir Infect 2000; 15: 195-207.
9. Geddes AM. Empiric therapy in lower respiratory tract infection: an ongoing challenge. J Chemother 1997; 9 (suppl 3): 5-9.
10. Cassiere HA, Niederman MS. Community-acquired pneumonia. Dis Mon 1998; 44 (11): 613-675.
11. Finch R. Community acquired pneumonia. J R Coll Physicians (Lond) 1998; 32 (4): 328-332.
12. Campbell GD Jr. The role of antimicrobial therapy in acute exacerbations of chronic bronchitis. Am J Med Sci 1999; 318 (2): 84-88.
13. Stratton CW. Introduction: PROTEKT against respiratory tract infection. J Chemother 14 (Suppl 3): 2002.
14. National Committee for Clinical Laboratory Standards (NCCLS). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved Standard - Fifth edition. NCCLS document M7-A5 (ISBN 1-56238-394-9). NCCLS 2000, Wayne, Pennsylvania 19087-1898, USA.
15. National Committee for Clinical Laboratory Standards (NCCLS). Performance standards for antimicrobial susceptibility testing; Twelfth informational supplement. NCCLS document M100-12 (ISBN 1-56238-454-6) NCCLS 2002, Wayne, Pennsylvania 19087-1898, USA.
16. Farrell DJ, Morrissey I, Bakker S, Felmingham D. Detection of macrolide resistance mechanisms in Streptococcus pneumoniae and Streptococcus pyogenes using a multiplex rapid cycle PCR with microwell-format probe hybridization. J Antimicrob Chemother 2001; 48: 541-544.
17. Felmingham D, Grüneberg R, and the Alexander Project Group. The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J Antimicrob Chemother 2000; 45: 191-203.
18. Jones ME, Karlowsky JA, Blosser-Middleton R, Critchley IA, Thornsberry C, Sahm DF. Apparent plateau in beta-lactamase production among clinical isolates of Haemophilus influenzae and Moraxella catarrhalis in the United States: results from the Libra surveillance initiative. Int J Antimicrob Agents 2002; 19:119-23.
19. Carbon C, Poole MD. The role of newer macrolides in the treatment of community-acquired respiratory tract infection. A review of experimental and clinical data. J Chemother 1999; 11: 107-18.
20. Balfour JA, Figgitt DP. Telithromycin. Drugs 2001; 61: 815-29.